SCHEMBL3668641

SCHEMBL3668641

CCCCN1CCC(=O)N(C)c2cnc(Cl)nc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 3/20 0.35
MITF O75030 1/20 0.35
LMNA P02545 1/20 0.35
ALPG P10696 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TSHR P16473 1/20 0.34
RAD52 P43351 1/20 0.33
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
ALOX15 P16050 1/20 0.32
ABL1 P00519 1/20 0.32
BCR P11274 1/20 0.32
RPS6KA3 P51812 2/20 0.31
INSR P06213 1/20 0.31
MET P08581 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3543105 0.86 SMN1; SMN2 (0.38) SMN1; SMN2RAD52CYP11B1CYP11B2ABL1
SCHEMBL3542695 0.84 KDM4E (0.37) ALDH1A1KDM4ELMNASMN1; SMN2RAD52
SCHEMBL3543713 0.84 RAD52 (0.38) ALDH1A1KDM4ESMN1; SMN2HSD17B10RAD52
SCHEMBL3543954 0.84 RPS6KA3 (0.45) SMN1; SMN2RAD52CYP11B1CYP11B2ABL1
SCHEMBL3543108 0.83 DRD2 (0.36) SMN1; SMN2RAD52PLK1DRD2DRD3
SCHEMBL3543738 0.82 SMN1; SMN2 (0.35) SMN1; SMN2RAD52CYP11B1CYP11B2ABL1
SCHEMBL3548150 0.82 RPS6KA3 (0.37) SMN1; SMN2NPC1RAB9ARAD52CYP11B1
SCHEMBL3538427 0.82 TLR9 (0.41) SMN1; SMN2
SCHEMBL3543190 0.81 TRPC5 (0.36) SMN1; SMN2RAD52CYP11B1CYP11B2PLK1
SCHEMBL3539514 0.81 SMN1; SMN2 (0.34) SMN1; SMN2RAD52CYP11B1CYP11B2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139892-A1 SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS F. Hoffmann-Roche AG (CH) 2010-01-06 EP disclosed
US-7517873-B2 Substituted pyrimidodiazepines HOFFMAN-LA ROCHE INC. (US) 2009-04-14 US disclosed
WO-2008113711-A1 SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-09-25 WO disclosed
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES PLK1, CCNI, CDK1 ALDH1A1 1365/4885KDM4E 1150/4885MITF 2637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.